Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-11-16
2003-10-07
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S220000
Reexamination Certificate
active
06630462
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to &dgr; receptor agonist compounds and their use in the treatment of pain. Specifically, tricyclic &dgr; receptor agonist compounds are disclosed, which have a tricyclic structure comprising a non-aromatic central ring flanked by two aromatic rings, and an optional pendant, substituted, piperazine or piperidine, together with their methods of use for the treatment of pain with reduced risk of induction of seizure in a patient.
BACKGROUND OF THE INVENTION
Clozapine (CLZ, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine) is an atypical antipsychotic or neuroleptic agent that is a dibenzodiazepine derivative with a piperazinyl side chain. It displays antipsychotic efficacy against positive and negative symptoms of schizophrenia in patients who do not respond to typical neuroleptics. It is metabolized via the hepatic microsomal enzyme system into two major metabolites: N-desmethylclozapine (DMCLZ) and clozapine N-oxide. DMCLZ has been shown to reach a plasma level of ~620 nM in human patients and is a potent 5HT1C receptor antagonist.
Clozapine inhibits binding at &dgr; opioid receptors (Kobayashi, T., Ikeda, K. & Kumanishi, T. (1998) Br. J. Pharmacol. 123:421-6). Clozapine also acts as a kappa agonist and as a G-protein-activated inwardly rectifying K
+
(GIRK) channel blocker. However, clozapine and other atypical antipsychotic agents frequently possess untoward side-effects, including induction of seizures. There is therefore a need, within the field of opioid receptor agonists, for compounds that are agonists of specific subtypes of opioid receptor that exhibit improved specificity and do not cause seizures.
The present invention addresses the aforementioned problems and more as will be apparent to one of skill in the art upon reading the following disclosure.
SUMMARY OF THE INVENTION
The present invention, in its broadest aspect, encompasses the use of &dgr; receptor agonist compounds for the treatment of pain, wherein the &dgr; receptor agonist compounds have a tricyclic structure comprising a non-aromatic central ring flanked by two or three aromatic rings, and an optional pendant, substituted, piperazine or piperidine.
In one embodiment, the invention therefore comprises the inducement of analgesia in a patient, where the methods comprise administering to a patient a &dgr; opioid receptor agonist of the general formula (I):
wherein:
rings A and B are aromatic rings of 5-7 carbons that are optionally substituted with one or more substituents that can include F, Cl, Br, I, —NO
2
, —OH, —SO
2
, or (C
1
-C
5
)alkyl;
C is carbon, X is N, O, S or P, and Y is N or P;
[m] is an integer of 0 or 1, [a] is an integer of from 0 to 2, and the sum [m]+[a] is an integer of from 0 to 2;
[n] is an integer of 0 to 1, [b] is an integer of 0 to 3, and the sum [n]+[b] is an integer of from 1 to 3;
the sum [m]+[a]+[n]+[b] is an integer of from 1 to 3; and
one C
[b]
or one Y
[n]
has a pendant substituted or unsubstituted piperidine or piperazine ring.
Another aspect of the invention relates to methods of inducing analgesia in a patient, wherein the methods comprise administering to said patient an effective amount of a tricyclic &dgr; opioid receptor agonist of the formula (Ia):
wherein:
X are each independently 0-4 substituents independently selected from the group consisting of F, Cl, Br, I, —NO
2
, —OH, —SO
2
, and (C
1
-C
5
)alkyl;
R
1
is C, N, O or S;
R
2
is C or N; and
R
3
is —H or —CH
3
.
Still another aspect of the invention relates to methods of inducing analgesia in a patient, wherein the methods comprise administering to said patient an effective amount of a tricyclic &dgr; opioid receptor agonist of the formula (Ib):
wherein:
X is F, Cl, Br, or I;
R
1
is C, N, O or S; and
R
3
is —H or —CH
3
.
Yet another aspect of the invention relates to methods of inducing analgesia in a patient, wherein the methods comprise administering to the patient an effective amount of a tricyclic &dgr; opioid receptor agonist of the formula (Ic):
wherein R is —H or methyl, with —H being preferred.
Still another aspect of the invention relates to methods of inducing analgesia in a patient, said method comprising administering to said patient an effective amount of a compound selected from the group consisting of N-desmethylclozapine, amoxapine, cyproheptadine, and mixtures thereof.
Still another aspect of the invention relates to methods of inducing analgesia in a patient, wherein the methods comprise administering to said patient an effective amount of a tricyclic &dgr; opioid receptor agonist of the formula (II):
wherein:
R
4
and R
5
are independently selected from alkyl, halo, haloalkyl, thio or alkoxy;
R
6
is C, N, O or S;
R
7
is C or N; and
R
8
is —H or —CH
3
.
These and other aspects of the invention will become more apparent from the following detailed description.
REFERENCES:
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: WO 97/35584 (1997-10-01), None
Jianquan, T., et al., “Analgesic and antipyretic effects of cyproheptadine,”Zhongguo Yaoli Xuebao, 1990, 11(13), 204-207 (Abstract only).
Kobayashi, T. et al., “Effects of clozapine on the §-k-opioid receptors and the G-protein-activated K+ (GIRK) channel expressed in Xenopus oocytes”British Journal of Pharmacology, 1998, 123, 421-6.
Martindale, The Extra Pharmacopoeia, 28th ed. published 1982 by The Pharmaceutical Press, pg. 115.
DeHaven Robert
Gauntner Erin
Little Patrick
Zhang Wei Y.
Adolor Corporation
Henley III Raymond
Woodcock & Washburn LLP
LandOfFree
Delta agonist analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delta agonist analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delta agonist analgesics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3163030